Feature Channels:

Alzheimer's and Dementia

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Business

Channels:

Alzheimer's Disease, Alzheimers disease, NeuroVision, A4 study , retinal imaging, beta-amyloid accumulation , Amyloid Plaque, Robert Rissman, Steve Verdooner

NeuroVision Announces Participation in Landmark Alzheimer’s A4 Study Evaluating Its Novel Retinal Imaging Technology

NeuroVision Imaging LLC (“NeuroVision”) today announced its participation in a new substudy with investigators at the University of California San Diego School of Medicine (UC San Diego) and the University of Southern California (USC) to be part of the landmark Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (or “A4”) clinical trial. The purpose of the A4 study is to test whether a new investigational treatment that may reduce beta-amyloid accumulation in the brain can also slow memory loss caused by Alzheimer’s disease.

Medicine

Channels:

Alzheimer's, Mild Cognitive Impairment, Genetic Test, Pharmacogenetics

Alzheimer’s Drug Prescribed ‘Off-Label’ for Mild Cognitive Impairment Could Pose Risk for Some

Donepezil, a medication that is approved to treat people with Alzheimer’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test.

Medicine

Channels:

New Mobile App Helps Families, Individuals Cope with Dementia

dementia-app-2v-271x4061.jpg

Researchers at the University of Illinois at Chicago College of Nursing have developed a free mobile app for individuals suffering from dementia, their families and caregivers, as a way to improve the quality-of-life, well-being and knowledge of the disease that affects nearly 48 million people worldwide.

Medicine

Channels:

alzheimer disease, Cognitive Decline, Aging, Latinos, Latino culture, Latino Health, Memory

New Study to Document Alzheimer’s Disease Risk Factors in Latinos

Rush University Medical Center has launched a unique, cohort study called Latino Core to learn about the aging process and risk factors for Alzheimer’s disease in older Latino adults.

Medicine

Channels:

short-term memory, Rutishauser, Mamelak, Memory Disorders

Cedars-Sinai Investigators Identify Human Brain Processes Critical to Short-Term Memory

Cedars-Sinai neuroscientists have uncovered processes involved in how the human brain creates and maintains short-term memories. This study is the first clear demonstration of precisely how human brain cells work to create and recall short-term memories. Confirmation of this process and the specific brain regions involved is a critical step in developing meaningful treatments for memory disorders that affect millions of Americans.

Medicine

Channels:

A Method Based on Artificial Intelligence Allows to Diagnose Alzheimer's or Parkinson's

133415_web.jpg

Researchers from the UGR and UMA have designed a technique that aims to model high-level data abstractions to make computers learn to differentiate the brain of a healthy person from that of an ill person by extracting the affected regions.

Medicine

Science

Channels:

Schizophrenia, Autism, neurologic disorder

Kennesaw State University Scientists Conducting Cutting-Edge Research

researchers.jpg

Two Kennesaw State University scientists have received a total of $737,364 in National Science Foundation and National Institutes of Health grants for developmental biology research into autism and birth defects.

Medicine

Channels:

Study: Hormone Therapy May Not Protect Against Alzheimer’s Disease

The latest study on hormone therapy and Alzheimer’s disease shows no relationship between taking the drugs and whether you may develop the disease years later. Some previous studies have shown that hormone therapy may increase the risk of the disease, while others have shown that it may reduce the risk. The new study was published in the February 15, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Medicine

Science

Channels:

Alzheimer's Disease, Calcium, cell energy, Mitochondria, Protein, Cell Culture, Gene, Disease Development, Pooja Jadiya, Alyssa A. Lombardi, Jonathan P. Lambert, Timothy S. Luongo, Jin Chu, Domenico Praticò, John W. Elrod, Temple University, Biophysical Society 61st Meeting, Biophysical Society

Imbalance of Calcium in a Cell's Energy Factory May Drive Alzheimer's Disease

Calcium in the mitochondria -- the energy factory of cells -- may be one of the keys to understanding and treating Alzheimer's disease and dementia. Researchers at Temple University have now identified how an imbalance of calcium ions in the mitochondria may contribute to cell death and, specifically, neurodegeneration in brain cells during Alzheimer's and dementia. The findings could eventually point to new therapies for preventing or delaying these diseases. The team will present its work during the 61st Meeting of the Biophysical Society.

Medicine

Channels:

Alzheimer's Disease, Peptides, Neurodegenerative Diseases, cell toxicity, amyloid hypothesis, Antonio De Maio, Isabel Rivera, David M. Cauvi , Nelson Arispe, University of California, San Diego, Biophysical Society 61st Meeting, Biophysical Society

New Understandings of Cell Death Show Promise for Preventing Alzheimer’s

Currently, the predominant theory behind Alzheimer’s disease is the “amyloid hypothesis,” which states that abnormally increased levels of amyloid beta (Aβ) peptides outside of brain cells produce a variety of low molecular weight Aβ aggregates that are toxic to the nervous system. These Aβ aggregates interact directly with target cells and lead to cell death. During the Biophysical Society’s meeting, being held Feb. 11-15, 2017, Antonio De Maio will present his work hunting for the specific mechanisms behind Aβ-induced toxicity to cells, or cytoxicity.







Chat now!